TY  - JOUR
AU  - Kaaks, Rudolf
AU  - Delorme, Stefan
TI  - Lung Cancer Screening by Low-Dose Computed Tomography - Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting [Lungenkrebs-Screening mittels Niedrigdosis-Computertomografie – Teil 1: Erwarteter Nutzen, mögliche Schäden und Kriterien für die Eignung und das Targeting der Bevölkerung].
JO  - RöFo
VL  - 193
IS  - 5
SN  - 1438-9010
CY  - Stuttgart [u.a.]
PB  - Thieme
M1  - DKFZ-2020-02513
SP  - 527-536
PY  - 2021
N1  - #EA:C020#LA:E010#2021 May;193(5):527-536
AB  - Trials in the USA and Europe have convincingly demonstrated the efficacy of screening by low-dose computed tomography (LDCT) as a means to lower lung cancer mortality, but also document potential harms related to radiation, psychosocial stress, and invasive examinations triggered by false-positive screening tests and overdiagnosis. To ensure that benefits (lung cancer deaths averted; life years gained) outweigh the risk of harm, lung cancer screening should be targeted exclusively to individuals who have an elevated risk of lung cancer, plus sufficient residual life expectancy. Overall, randomized screening trials show an approximate 20 
LB  - PUB:(DE-HGF)16
C6  - pmid:33212540
DO  - DOI:10.1055/a-1290-7926
UR  - https://inrepo02.dkfz.de/record/165964
ER  -